Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference

NEW YORK--()--Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York. Thomas Lynch, chief scientific officer, will answer questions about the company at 11:00 a.m. EDT.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitter, YouTube and Facebook.

Contacts

Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Investors:
Tim Power, 609-252-7509
timothy.power@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com

Release Summary

Bristol-Myers Squibb to Take Part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference

$Cashtags

Contacts

Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Investors:
Tim Power, 609-252-7509
timothy.power@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com